Sensus Healthcare, Inc. (SRTS)

Several events have impacted Sensus Healthcare's stock price and investor sentiment in the past six months. In Q3 2025, Sensus Healthcare reported an EPS of -$0.06, surpassing estimates, with quarterly revenue exceeding expectations. In Q2 2025, revenues decreased compared to the prior year, with a net loss and lower gross margin. A proposed Local Coverage Determination impacted domestic sales momentum in Q2 2025, while a proposed Physician Fee Schedule is expected to favorably impact SRT technology adoption in 2026. Several insiders purchased company stock in November 2025. Eric Sachetta and Larry Biscotti were appointed to the Board of Directors in November 2025 and January 2026, respectively. President Michael Sardano's role was expanded to include Chief Commercial Officer in November 2025. Sensus Healthcare appointed Carr, Riggs & Ingram as its new auditor in January 2026. Over the past year, SRTS underperformed the US Medical Equipment industry and the broader US Market.

Sensus Healthcare's product and service demand exhibits some seasonality, with revenue in the second half of the year expected to be higher than the first half. Q2 revenue is generally expected to be higher than Q1 revenue. May as Skin Cancer Awareness Month, could potentially influence demand for their skin cancer treatment solutions.

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions. The company operates within the Healthcare sector, specifically in the Medical Devices and Instruments industry and is a pioneer in developing and delivering non-invasive treatments for skin cancer and keloids. The core of Sensus Healthcare's technology platform is superficial radiotherapy (SRT and image-guided SRT, or IG-SRT), which utilizes low-energy X-rays. Its major products include SRT-100™, SRT-100+™, SRT-100 Vision™, Sentinel software and service program, and a Transdermal Infusion system. The company also sells disposable lead shielding replacements, disposable radiation safety items, and distributes laser devices for various applications.

Sensus Healthcare generates a substantial portion of its revenue from customers in the United States. The company also has an expanding international footprint, with SRT systems shipped to international markets, including China, and is laying groundwork for broader expansion following MDSAP certification.

Sensus Healthcare's brand reputation has been positively impacted by its recognition on TIME's list of America's Growth Leaders of 2026. The company emphasizes its commitment to delivering safe, effective, non-invasive, and cost-effective treatments for skin conditions, positioning its technology as a patient-centric alternative to surgery. The company's focus on expanding market reach and demand also contributes to a positive perception.

Sensus Healthcare, Inc. has 83 institutional owners and shareholders, including Vanguard Group Inc. and Pacific Ridge Capital Partners, LLC. Individual insiders who own company stock include Joseph C. Sardano and Eric Sachetta. Institutions hold 27.27% of the shares outstanding, while individuals/insiders hold 17.72%.